Does a retrospective analysis of the impact of 18F-FDG PET scan on clinical management of 133 breast cancer patients?
PET holds promise as a sensitive and specific modality in following treated breast cancer patients. PET results contain information on 6 month outcome that is independent of stage or past treatment and influence patient management.
In summary, we show that AQP4-reactive T cells are sufficient to trigger an NMO-like disease in mice, independent of antibodies, indicating that pathogenic AQP4-reactive T cells may play a similar role in humans.